Fig. 1 · Structure

Documents & Downloads

Lacidipine

Cat. No. A11729 CAS 103890-78-4
Lacidipine is a calcium channel blocker

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vitro Studies

In GD fibroblasts, Lacidipine at 10 µM for 24 hrs increased Bcl-2 expression by 3.0-fold compared with untreated cells. In Vero cells incubated with and without Lacidipine, GTOVpv and MOPVpv exhibited dose-dependent inhibition, with IC50s of 6.2 μM and 4.8 μM, respectively. In fibroblasts derived from GD patients homozygous for the L444P GC allele, Lacidipine at 20 µM for 48 hrs produced a 1.8-fold GC activity response compared with untreated cells. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Bcl-2 expression in GD fibroblasts

Cell-based study · GD fibroblasts [1]

GD fibroblasts were cultured with Lacidipine at 10 µM for 24 hrs. Treatment increased Bcl-2 expression by 3.0-fold compared with untreated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Bcl-2 expressionBcl-2 expression 3.0-fold increase[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
24 hrs
Method
cells cultured with lacidipine
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Lacidipine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Lacidipine Remodels EerI-mediated Activation of the UPR Pathway (S77, S78); Figure 4 legend (S151)

Bcl-2 expression: Bcl-2 expression; comparator: untreated cells — Results > Lacidipine Remodels EerI-mediated Activation of the UPR Pathway (S77, S78)

Pseudotype inhibition in Vero cells

Cell-based study · Vero cells [2]

Vero cells were incubated in the absence and presence of Lacidipine, with luciferase activity assessed after pseudotype exposure. GTOVpv and MOPVpv exhibited dose-dependent inhibition, with IC50s of 6.2 μM and 4.8 μM, respectively.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
luciferase activityIC50 6.2 μM[2]

Literature-Reported Treatment Conditions

Exposure duration
After 1 h, the pseudotypes of GTOV, JUNV, MACV, SABV, CHPV, LCMV, LUJV, MOPV, EBOV, and MARV were added at an MOI of 0.01. The supernatant was removed 1 h later, and the cell lysates were assessed for luciferase activity after 23 h.
Method
incubated in the absence and presence of lacidipine
Co-treatment
Other interventions in this design: GTOV MOI of 0.01. Compound effect isolated by the comparison: in the absence and presence of lacidipine.
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Lacidipine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Lacidipine affects entry of other arenaviruses. (S70); FIG 6 legend (S185, S186, S187)

luciferase activity: luciferase activity; comparator: in the absence and presence of lacidipine — RESULTS > Lacidipine affects entry of other arenaviruses. (S70); FIG 6 legend (S187)

GC activity in patient-derived GD fibroblasts

Cell-based study · fibroblasts derived from GD patients homozygous for the L444P GC allele [1]

Fibroblasts derived from GD patients homozygous for the L444P GC allele were cultured with Lacidipine at 20 µM for 48 hrs. The intact cell GC activity assay showed a 1.8-fold response compared with untreated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
intact cell GC activity assayGC activity 1.8-fold[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 µM
Exposure duration
48 hrs
Method
cultured in medium
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Lacidipine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Modulation of Ca2+ Homeostasis Enhances the Rescue of L444P GC Folding, Trafficking and Activity Induced by ERAD Inhibition in GD Fibroblasts (S13, S14, S15, S17, S18); Figure 1 legend (S133)

intact cell GC activity assay: intact cell GC activity assay; comparator: untreated cells — Results > Modulation of Ca2+ Homeostasis Enhances the Rescue of L444P GC Folding, Trafficking and Activity Induced by ERAD Inhibition in GD Fibroblasts (S15, S18)

In Vivo Studies

Female BALB/c mice bearing 4T1‐Luc breast tumors received oral Lacidipine at 10 mg kg−1 or 20 mg kg−1 every 2 d. Lacidipine significantly inhibited tumor growth rate compared with the vehicle control group. [3]

Tumor growth inhibition in breast tumor-bearing mice

Animal study · Female BALB/c mice (6–8 weeks); 4T1‐Luc breast tumor‐bearing; n = 12 per group [3]

Female BALB/c mice bearing 4T1‐Luc breast tumors received oral Lacidipine at 10 mg kg−1 or 20 mg kg−1 every 2 d. Lacidipine significantly inhibited tumor growth rate compared with the vehicle control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume was measured using a Vernier caliper every 3 d for up to 21 dReported result significantly inhibited the growth rate of the tumor[3]

Conditions shared by the study groups

Route
p. o.
Treatment course
every 2 d
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lacidipine 10 mg kg−1; 20 mg kg−1vehiclesignificantly inhibited the growth rate of the tumor[3]
Lacidipine 10 mg kg−1; 20 mg kg−1
Model: Female BALB/c mice (6–8 weeks); 4T1‐Luc breast tumor‐bearing; n = 12 per group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Lacidipine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Lacidipine Exerts Potential Antitumor Effects In Vivo (S20, S26); Experimental Section > In Vivo Tumor Experiments (S198, S202, S203, S204); Figure 2 legend (S257)

Tumor volume was measured using a Vernier caliper every 3 d for up to 21 d: Tumor volume was measured using a Vernier caliper every 3 d for up to 21 d; comparator: vehicle — Results > Lacidipine Exerts Potential Antitumor Effects In Vivo (S26); Experimental Section > In Vivo Tumor Experiments (S204)

Lacidipine 10 mg kg−1; 20 mg kg−1 · Results > Lacidipine Exerts Potential Antitumor Effects In Vivo (S26); Experimental Section > In Vivo Tumor Experiments (S202, S203)

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 103890-78-4
Formula C26H33NO6
Molecular Weight 455.54
Synonyms Lacipil; Motens
SMILES
CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 86 mg/mL (188.78 mM)
Water Insoluble
Ethanol 21 mg/mL (46.1 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wang F, Segatori L. Remodeling the proteostasis network to rescue glucocerebrosidase variants by inhibiting ER-associated degradation and enhancing ER folding. PLoS One (2013). PMID: 23620750 DOI: 10.1371/journal.pone.0061418 Source material
  2. [2] Wang P, Liu Y, Zhang G, et al. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. J Virol (2018). PMID: 29899092 DOI: 10.1128/JVI.00954-18 Source material
  3. [3] Sheng Y, Qiao C, Zhang Z, et al. Calcium Channel Blocker Lacidipine Promotes Antitumor Immunity by Reprogramming Tryptophan Metabolism. Adv Sci (Weinh) (2025). PMID: 39585774 DOI: 10.1002/advs.202409310 Source material

Added to your cart

View Cart Checkout
Loading...